An imipenem-resistant mutant of Proteus mirabilis lacked a 26 kDa outer membrane protein (OMP). It has previously been postulated that this protein is a porin, but the present mutant, which was cross-resistant to mecillinam but not to other -lactams, proved as permeable to carbapenems as its parent. A mecillinam-selected mutant had similar cross-resistance yet retained the 26 kDa OMP, confirming that this protein was not important to resistance. In contrast, cefoxitin-selected mutants retained the 26 kDa protein but had diminished expression of major 41 and 44 kDa OMPs and showed reduced uptake of carbapenems, although this promoted resistance only when a carbapenemase was also present. We conclude that the imipenem-selected mutant owed its resistance to some factor other than porin loss, probably to a lesion in penicillin-binding protein 2. †Present address:
Introduction
MIC 90 s of imipenem are 1 mg/L for most Enterobacteriaceae, but are 4-8 mg/L for Proteeae; 1,2 moreover, imipenem is less bactericidal for Proteeae than for other enterobacteria. 3 This relative insusceptibility has not caused major clinical problems, but failure of imipenem to eradicate Proteus mirabilis from soft-tissue infections has been reported, 4, 5 as has post-treatment colonization by the organism. [6] [7] [8] A few P. mirabilis isolates are more resistant, with imipenem MICs ranging from 16 to 64 mg/L, and single-step mutants with these levels of resistance can be isolated in vitro. 9, 10 -Lactamases are not implicated; rather, one resistant isolate (MIC 32 mg/L)-from a patient who had not received imipenemlacked a 24 kDa outer membrane protein (OMP) that was also lost by imipenem-selected laboratory mutants. 9 Two other relatively resistant isolates (MIC 8 mg/L), from patients who had received imipenem, had diminished expression of penicillin-binding protein (PBP) 1a and reduced binding of imipenem by PBP2, but retained normal OMP profiles.
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To test the role of impermeability in imipenemresistant P. mirabilis we undertook penetration assays on a parent strain and its mutants and related the permeability coefficients to OMP profiles.
Materials and methods

Strains
The P. mirabilis variants (Table I) were all derivatives of strain Pm1, which was isolated from the urine of a 36-year-old woman with cystitis. It was identified by its reactions in an API20E strip (BioMérieux, La Balme les Grottes, France) and its -lactamases were examined by isoelectric focusing. 12 In addition, Escherichia coli JM109 (pPTN1) and its cefoxitin-resistant mutant were used. Plasmid pPTN1 encodes NMC-A -lactamase, a Class A enzyme able to hydrolyse carbapenems. 13 Methods for obtaining resistant mutants and transformants of strains Pm1 and E. coli JM109 were as described below.
Isolation of TEM-1 -lactamase-deficient mutants of strain
Pm1. Logarithmic phase cultures were grown, with shaking, at 37°C in 10 mL volumes of Nutrient Broth No. 2 (Unipath, Basingstoke, UK), to a density of approximately 5 10 8 cfu/mL. Ethyl methane sulphonate (EMS) was added at 0.5% (v/v) and incubation was continued for 60 min without shaking. The cultures were then diluted 30-fold into fresh, warm broth and incubated for 3 h to allow expression of mutations. Serial ten-fold dilutions were then spread on nutrient agar containing boric acid 0.1% to prevent swarming. Plates yielding 100-200 colonies were flooded with 10 mL of a mixture comprising 0.2% iodine; 2% potassium iodide and 0.6% benzylpenicillin in 80% strength Mueller-Hinton agar andlactamase-deficient organisms were recognized by a failure to form clear haloes. Nitrocefin tests confirmed the absence of the enzyme.
Selection of antibiotic-resistant mutants. Overnight broth cultures were concentrated 100-fold by centrifugation at 5000g for 15 min, and 100 L volumes were spread on cysteine lactose electrolyte-deficient (CLED, Unipath) agar containing imipenem, 4 or 8 mg/L; mecillinam, 50 mg/L or cefoxitin, 16 or 32 mg/L. After 72 h incubation at 37°C, single colonies were subcultured on to drug-free CLED agar and screened for resistance with discs (Unipath). Mutants with stable resistance were retained for study.
Transformation of pPTN1 into P. mirabilis cultures. Plasmid pPTN1 was purified from E. coli JM109 (pPTN1) by the Qiagen protocol (Diagen, Hilden, Germany) and transformed into Pm1 derivatives by electroporation using an EasyJect Apparatus in accordance with the protocols advised by its manufacturer (Phillip Harris, Shenstone, Lichfield, UK). The potential difference was 2500 V, with a capacity of 25 F and a pulse time of 5 ms. Transformants were selected on CLED agar containing ampicillin, 100 or 200 mg/L.
Antibiotics and susceptibility tests
Antimicrobials were provided by suppliers as follows: ampicillin sodium (SmithKline Beecham, Brentford, UK), mecillinam (Leo, Princes Risborough, UK), cefoxitin and imipenem (Merck Sharp and Dohme, Hoddesdon, UK), amikacin and aztreonam (Hounslow, UK), cefotaxime (Roussel, Uxbridge, UK), meropenem (Zeneca, Macclesfield, UK), chloramphenicol and gentamicin (Sigma Chemical Co., St Louis, MO, USA), tobramycin (Lilly, Basingstoke, UK), ciprofloxacin (Bayer, Newbury, UK), tetracycline (Lederle, Gosport, UK) and isepamicin (Schering Plough, Bloomfield, NJ, USA). MICs were determined on Diagnostic Sensitivity Test agar (Unipath) with an inoculum of 10 4 cfu/spot.
OMP profiles
Membranes were obtained from French pressates of logarithmic phase cultures grown in Antibiotic Medium No. 3. The outer membrane fraction was separated by sucrose gradient centrifugation, then subjected to SDS-PAGE. Methods were exactly as described previously for Pseudomonas aeruginosa membranes. 14 
Permeability assays
Permeability was measured by the method of Zimmermann & Rosselet. 15 Starter cultures were grown overnight on an orbital shaker at 37°C in 10 mL of Antibiotic Medium No. 3 (Penassay broth), then added to 100 mL of identical medium, pre-warmed to 37°C. Incubation was continued for 4 h, after which the cells were harvested at 5000g and 37°C and resuspended in 10 mL of 0. 
. Finally, the membrane permeability coefficient, C, was calculated from Fick's law of diffusion, rearranged as:
Results
Antibiotic susceptibility of isolate Pm1 and its derivatives
MICs for Pm1, its mutants and their pPTN1-containing transformants are shown in Table I . Strain Pm1 had a pI 5.4 -lactamase, probably the TEM-1 enzyme. To preclude interference in permeability assays, the gene for this enzyme was inactivated with EMS, after less drastic methods failed. Loss of the enzyme reduced the MICs of ampicillin and mecillinam but not those of the otherlactams. These findings were consistent with the view that the enzyme was TEM-1. Resistance to gentacmicin was also lost from Pm1 -, possibly because a plasmid that encoded TEM-1 and an aminoglycoside-modifying enzyme was eliminated by EMS treatment. The imipenem-selected mutant, Pm1 imp R -, had 16-fold increased resistance to imipenem and 256-fold increased resistance to mecillinam, as compared with Pm1 -, whereas MICs of ampicillin, cefoxitin, aztreonam, cefotaxime and meropenem were increased fourfold or less. Surprisingly, MICs of aminoglycosides were also increased. The mecillinam-selected mutant, Pm1 -mec R , resembled Pm1 imp R -in exhibiting greater increases in resistance to mecillinam (especially) and imipenem than to other -lactams, but differed in showing no increased resistance to aminoglycosides. The cefoxitinselected mutant, Pm1 -fox R , was very different: MICs of cefoxitin and mecillinam were increased 16-to 64-fold, but those of other -lactams, including imipenem, were increased four-fold or less, and MICs of aminoglycosides were unaltered.
Three separate pPTN1 transformants of strain Pm1 -, three of Pm1 imp R -and two of Pm1 -fox R , were subjected to MIC tests. Results were similar within each series and values for one representative of each are shown in Table I . Acquisition of the NMC-A -lactamase determined by pPTN1 raised the MICs of all -lactams except cefoxitin and its effects were cumulative with the resistances selected by mutation. Thus, the MIC of imipenem for Pm1 imp R -(pPTN1) was 16-fold higher than for Pm1 -(pPTN1); similarly, Pm1 -fox R (pPTN1) was eight-to 32-fold more resistant to meropenem than were Pm1 -(pPTN1) and Pm1 imp R -(pPTN1).
OMP profiles
Outer membrane profiles are shown in the Figure. A 26 kDa OMP was lost from Pm1 imp R -but retained by Pm1 -mec R and Pm1 -fox R . On the other hand, Pm1 -fox R had diminished amounts of the two major OMPs, with molecular masses of 44 and 41 kDa. E. coli JM109 fox R completely lacked a 41 kDa protein that was prominent in the parent strain
Outer membrane permeability
NMC-A -lactamase allowed sufficiently rapid hydrolysis of both imipenem and meropenem for V i rates to be measured; moreover, enzyme leakage was minimal and values of C were independent of S o for all transformants. We therefore considered the Zimmermann & Rosselet 15 procedure to be valid. However, in applying the method we found much higher K m 's of carbapenems than were reported previously for the NMC-A enzyme: 478 218 M for imipenem, based on 17 experiments, compared with a published value of 95 M; 13 and 29 7 M for meropenem, based on nine experiments, compared with a published value of 7 M. 13 We have no explanation, except noting that the present assays were by spectrophotometry whereas the previous studies were by microacidometry and that discrepancies between these methods have been noticed previously. 16 Permeability assays were performed with three pPTN1 transformants each of Pm1 -and Pm1 imp R -, and with one of Pm1 -fox R . As a control, assays were performed with E. coli JM109 pPTN1 and with its cefoxitin-selected mutant. Despite their lack of the 26 kDa protein, transformants of Pm1 imp R -were as permeable to both carbapenems as were the transformants of Pm1 -, or were slightly more permeable (Table II) . In contrast, the cefoxitin-selected mutants of P. mirabilis Pm1 and E. coli JM109 both showed markedly decreased permeability to both carbapenems (lower C values).
Discussion
Mehtar et al. 9 noted the absence of a 24 kDa OMP from an imipenem-resistant P. mirabilis isolate and imipenemselected laboratory mutants. An analogous loss was noted in Pm1 imp R -, where we estimated that the molecular mass of the protein as 26 kDa. This association suggested that the protein might be a porin and that resistance might be contingent on impermeability. By analogy, loss of OprD ('D2 porin') engenders imipenem resistance in P. aeruginosa, and diminished expression of porins OmpC and OmpF reduces insusceptibility to many -lactams in E. coli. 17, 18 Nevertheless, it is tenuous to attribute resistance to impermeability on the sole evidence of OMP loss, as single pleiotropic mutations, for example to the mar system of enterobacteria, can simultaneously reduce porin expression and increase non-specific efflux, with both factors contributing to resistance. 19 Moreover, 24-26 kDa is unusually small for a porin, though not impossibly so, 20 and mecillinam-selected mutants of Pm1 had an identical -lactam-resistance phenotype to Pm1 imp R -, yet retained the 26 kDa protein.
Based on these concerns we undertook direct permeability assays, comparing entry of imipenem and meropenem into the parent P. mirabilis strain, its imipenem-selected mutant (lacking the 26 kDa protein) and its cefoxitin-selected mutant. The latter mutant retained the 26 kDa OMP and was fully susceptible to imipenem, but had reduced expression of the major 41 and 44 kDa OMPs, the smaller of which has previously been suggested to be a general porin of P. mirabilis. 21 Assays showed that the cefoxitin mutant, but not the imipenem mutant, had reduced permeability to the carbapenems; similarly, a cefoxitin-selected mutant of E. coli JM109 lacking a 41 kDa OMP, probably OmpF, showed diminished permeability to meropenem (Table II) .
We conclude that loss of the 26 kDa OMP had no bearing on imipenem resistance, although it may relate to the aminoglycoside resistance simultaneously developed by Pm1 imp R -. Rather, two lines of evidence suggest that the imipenem resistance reflected changes to PBP2. First, MICs of imipenem and mecillinam were increased more than those of other -lactams for both the Pm1 imp Rand Pm1 -mec R , and both these compounds bind preferentially, or solely in the case of mecillinam, to PBP2, whereas the other -lactams tested bind predominantly to PBP3 22, 23 or, in the case of meropenem, to both PBPs 2 and 3. 24 Secondly, Neuwirth et al. 11 found reduced affinity of PBP2 in two imipenem-insusceptible (MIC 8 mg/L) P. mirabilis isolates. Unfortunately, PBP affinity assays on the present mutants were unsuccessful, with PBP2 not reproducibly detected (not shown).
Impermeability to carbapenems, as engendered by diminished expression of the 41 and 44 kDa OMPs did not, alone, give resistance to these compounds (Table I) . This observation is consistent with the view 17, 18 that, even in porin-deficient mutants, -lactam uptake is so rapid, relative to growth, that MICs are only increased iflactamase or efflux removes drug molecules from the periplasm. We surmise that no such factor existed in Pm1 -fox R ; once, however, the NMC-A enzyme was present it gave greater resistance, particularly to meropenem, in the less permeable background of Pm1 -fox R than in the parent Pm1 -strain.
A final aspect of note concerns the greater anti-Proteus activity of meropenem than imipenem. Whereas the MIC 90 of imipenem for P. mirabilis is 4-8 mg/L, that of meropenem is below 0.5 mg/L. 24 Data for Pm1 -(pPTN1) (Table II) show that the improved activity of meropenem does not reflect accelerated permeation; rather meropenem was a ten-fold slower permeant than imipenem, and it seems likely that the potency of this newer carbapenem reflects increased target affinity. 
